: iStockAnalyst.com Symbols Feed

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

Pfizer (PFE) Reports; Should I Sell My Shares?

Tue, 20 Oct 2009 15:45:27 GMT

Now that I own some Pfizer stock (due to the acquisition of Wyeth), I feel obligated to at least post on Pfizer's earnings. (marketwatch) -The world's largest drug maker posted net income of $2.88 billion, or 43 cents a share, compared with $2.28 billion, or 34 cents a share, for the same quarter[More...]

Pfizer (PFE) Big Penalty

Mon, 19 Oct 2009 17:20:37 GMT

Following the recent merger of Pfizer (PFE) and Wyeth, a U.S. court imposed a huge fine on the company’s subsidiary Pharmacia & Upjohn for fraudulent marketing of its painkiller Bextra (valdecoxib). The penalty of $1.195 billion was the largest criminal fine ever imposed in the U.S. In addition, a criminal forfeiture of $105 million was enforced on the company.[More...]

Pfizer (PFE) Wastes No Time Realizing Cost Efficiencies

Fri, 16 Oct 2009 16:25:52 GMT

The largest deal among drug makers in the last year was completed today as Pfizer (PFE) officially merged with Wyeth (WYE). At the close of trading on Thursday, Wyeth was delisted from the NYSE. Pfizer has wasted no time in announcing some of its plans for what to do with its newest asset. Cutting costs will be a top priority as the company has announced closure of Wyeth operations in Pennsylvania and New Jersey.[More...]

BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI

Wed, 14 Oct 2009 16:31:04 GMT

On 10/14/09, Progenics Pharma (NASDAQ: PGNX) announced a deal with Wyeth to re-acquire all of the worldwide rights to the RELISTOR franchise after a one-year transition period. RELISTOR (subcutaneous injection) is the only drug approved to treat opioid-induced constipation (OIC) in patients with advanced illness receiving palliative care.[More...]

The Return Of The Financial Dividends

Fri, 02 Oct 2009 13:11:29 GMT

The financial crisis lead to dividend cuts amongst several prominent dividend payers such as Bank of America (BAC), US Bancorp (USB) and BB&T Corp. (BBT). Over the past few weeks however, several financial companies announced that they might reconsider their current dividend policies and start raising distributions in the near future.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Are High Dividend Stocks Worth It?

Wed, 16 Sep 2009 13:27:44 GMT

As an investor in the accumulation stage, I tend to focus on companies with yields of at least 3% and expectations of future dividend growth.[More...]

Pharma Majors To Gain From India

Wed, 19 Aug 2009 03:28:58 GMT

All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to grow at 12.3% through 2014 surpassing many other economies in the emerging markets. Many of these[More...]

FDA Calendar Updates: MELA, PGNX, VPHM, WYE, NeurogesX, Thoratec

Thu, 06 Aug 2009 15:24:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

Pfizer profit jumps 26 percent on cost cutting

Tue, 20 Oct 2009 11:51:00 GMT

NEW YORK - Pfizer Inc. posts a higher third-quarter profit despite the recession, as sharp cost cuts make up for slightly lower sales.
That was up 26 percent from last year, when the company had a huge legal charge over promotion of its painkillers.
Pfizer will keep cutting costs, now that it has completed the biggest drug industry deal of the year.

: iStockAnalyst.com Symbols Feed

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Pfizer (PFE) Reports; Should I Sell My Shares?

Pfizer (PFE) Big Penalty

Pfizer (PFE) Wastes No Time Realizing Cost Efficiencies

BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI

The Return Of The Financial Dividends

Which Pharma Pipelines Rank Best?

Are High Dividend Stocks Worth It?

Pharma Majors To Gain From India

FDA Calendar Updates: MELA, PGNX, VPHM, WYE, NeurogesX, Thoratec

Pfizer profit jumps 26 percent on cost cutting

The Business Diary

Pfizer Completes Takeover of Wyeth

Heads Up | Southwest Airlines Adds Flight Between KC and Baltimore

EDITORIAL: Don't Wait on Pfizer

Pa. Isn't Expected to Lose Jobs When Pfizer Acquires Wyeth

Stock Market, Economy Heading Back to 'Normal'

Pa. Isn't Expected to Lose Jobs When Pfizer Acquires Wyeth

Stock Market, Economy Heading Back to 'Normal'

Pfizer, Wyeth deal gets clearance in China

Pfizer Reports Third-Quarter 2009 Results

IQPC's Corporate Energy Management Summit to Feature Experts From, EMC, the EPA, and the DOE

Stock on the Move: SUWN - October 15, 2009

Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09

Cylex, Inc. Appoints Brad L. Stewart As Chief Executive Officer and Chairman of the Board

Metastorm Debuts New Customer Testimonial Videos ; Seven Successful Organizations Share Insights on Using EA, BPA, BPM Software in Season 5 of the 'Metastorm Customers Speak Out' Series

Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024

StockPreacher.com Issues Trading Outlook for Nabi Biopharmaceuticals

Wyeth Provides Regulatory Update on Prevnar 13* in the United States

Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook

Form 4 WYETH For: Oct 15 Filed by: STEIN LAWRENCE V (10K)

Form 4 WYETH For: Oct 15 Filed by: Wold Mary Katherine (10K)

Form 4 WYETH For: Oct 15 Filed by: TORELL JOHN R III (10K)

Form 4 WYETH For: Oct 15 Filed by: Redmond Cavan M. (10K)

Form 4 WYETH For: Oct 15 Filed by: POUSSOT BERNARD J (10K)

Form 4 WYETH For: Oct 15 Filed by: ROGERS GARY L (10K)

Form 4 WYETH For: Oct 15 Filed by: Portwood Charles A (10K)

Form 4 WYETH For: Oct 15 Filed by: POLAN MARY LAKE PH D (10K)

Form 4 WYETH For: Oct 15 Filed by: Peppard Denise M. (10K)

Form 4 WYETH For: Oct 15 Filed by: Norden Gregory (10K)